Intravitreal Avastin in Proliferative Retinopathies
- Registration Number
- NCT00564148
- Lead Sponsor
- Ophthalmological Association Edelweiss
- Brief Summary
The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes
- Detailed Description
Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments.
Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc)
- distance acuity < 0.5
- age > 20 years
- noncooperative patients
- ocular infections / inflammations
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A,1, II Avastin -
- Primary Outcome Measures
Name Time Method The following parameters will be assessed in order to evaluate the Avastin effect: visual acuity, lesions's area at the ocular fundus one year
- Secondary Outcome Measures
Name Time Method The intraocular pressure will be measured during the whole study in order to assess the possible side effects of Avastin injections one year
Trial Locations
- Locations (1)
Ochiul Diabetic
🇷🇴Iasi, Romania